CR Pharma completes RMB 1.00 billion first-tranche medium-term note issue at 1.53% coupon

Bulletin Express07-22

China Resources Pharmaceutical Group Limited (abbreviated as CR Pharma) announced that its wholly owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, has finalised the issuance of the first tranche of its 2026 medium-term notes in mainland China.

The offering, completed on 21 July 2026, raised RMB 1.00 billion through three-year notes carrying an annual coupon of 1.53%. According to the filing, proceeds will be allocated to replenish working capital, repay interest-bearing debt and for other uses permitted under applicable laws and regulations.

The transaction is classified as inside information under Hong Kong Listing Rule 13.09 and Part XIVA of the Securities and Futures Ordinance. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.

The board is chaired by Mr Bai Xiaosong, with a total of 12 directors comprising executive, non-executive and independent non-executive members. All information above is drawn directly from the company’s disclosure dated 22 July 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1111875986?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-22 18:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111875986","market":"us","top_or_hot":-1,"title":"CR Pharma completes RMB 1.00 billion first-tranche medium-term note issue at 1.53% coupon","media":"Bulletin Express","content":"<p>China Resources Pharmaceutical Group Limited (abbreviated as CR Pharma) announced that its wholly owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, has finalised the issuance of the first tranche of its 2026 medium-term notes in mainland China.</p>\n<p>The offering, completed on 21 July 2026, raised RMB 1.00 billion through three-year notes carrying an annual coupon of 1.53%. According to the filing, proceeds will be allocated to replenish working capital, repay interest-bearing debt and for other uses permitted under applicable laws and regulations.</p>\n<p>The transaction is classified as inside information under Hong Kong Listing Rule 13.09 and Part XIVA of the Securities and Futures Ordinance. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.</p>\n<p>The board is chaired by Mr Bai Xiaosong, with a total of 12 directors comprising executive, non-executive and independent non-executive members. All information above is drawn directly from the company’s disclosure dated 22 July 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CR Pharma completes RMB 1.00 billion first-tranche medium-term note issue at 1.53% coupon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCR Pharma completes RMB 1.00 billion first-tranche medium-term note issue at 1.53% coupon\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-22 18:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Resources Pharmaceutical Group Limited (abbreviated as CR Pharma) announced that its wholly owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, has finalised the issuance of the first tranche of its 2026 medium-term notes in mainland China.</p>\n<p>The offering, completed on 21 July 2026, raised RMB 1.00 billion through three-year notes carrying an annual coupon of 1.53%. According to the filing, proceeds will be allocated to replenish working capital, repay interest-bearing debt and for other uses permitted under applicable laws and regulations.</p>\n<p>The transaction is classified as inside information under Hong Kong Listing Rule 13.09 and Part XIVA of the Securities and Futures Ordinance. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.</p>\n<p>The board is chaired by Mr Bai Xiaosong, with a total of 12 directors comprising executive, non-executive and independent non-executive members. All information above is drawn directly from the company’s disclosure dated 22 July 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03320","symbol_name":"华润医药","start_time":0,"source_url":"","article_id":"1111875986","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111875986","pubTimestamp":1784715639,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"China Resources Pharmaceutical Group Limited (abbreviated as CR Pharma) announced that its wholly owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, has finalised the issuance...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03320":"华润医药"},"translate_title":"华润医药以1.53%票面完成首批10亿元中期票据发行","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":1},"content_text":"China Resources Pharmaceutical Group Limited (abbreviated as CR Pharma) announced that its wholly owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, has finalised the issuance of the first tranche of its 2026 medium-term notes in mainland China.\nThe offering, completed on 21 July 2026, raised RMB 1.00 billion through three-year notes carrying an annual coupon of 1.53%. According to the filing, proceeds will be allocated to replenish working capital, repay interest-bearing debt and for other uses permitted under applicable laws and regulations.\nThe transaction is classified as inside information under Hong Kong Listing Rule 13.09 and Part XIVA of the Securities and Futures Ordinance. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.\nThe board is chaired by Mr Bai Xiaosong, with a total of 12 directors comprising executive, non-executive and independent non-executive members. All information above is drawn directly from the company’s disclosure dated 22 July 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1111875986","isCrawlerRequest":true}